Compare Stocks: ABVC, ZYBT, CING, and LONA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$0.95 -5.5%	$1.17	$0.71 ▼ $3.40	$25.18M	0.61	104,774 shs	58,865 shs
CING Cingulate	$5.16 -1.2%	$5.06	$3.16 ▼ $11.89	$74.88M	-0.88	427,084 shs	8,223 shs
LONA Athira Pharma	$7.55 -2.0%	$8.07	$3.52 ▼ $14.21	$70.85M	2.05	51,711 shs	2,469 shs
ZYBT Zhengye Biotechnology	$1.65 +1.2%	$1.51	$0.62 ▼ $11.45	$78.19M	-2.56	2.03 million shs	6,901 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	+15.67%	+25.68%	-6.54%	-24.81%	-63.10%
CING Cingulate	+1.36%	-4.04%	+6.53%	+16.26%	+41.08%
LONA Athira Pharma	+0.39%	-2.41%	+0.52%	-6.33%	+769,999,900.00%
ZYBT Zhengye Biotechnology	0.00%	-7.39%	+27.34%	+96.27%	-83.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$0.95 -5.5%	$1.17	$0.71 ▼ $3.40	$25.18M	0.61	104,774 shs	58,865 shs
CING Cingulate	$5.16 -1.2%	$5.06	$3.16 ▼ $11.89	$74.88M	-0.88	427,084 shs	8,223 shs
LONA Athira Pharma	$7.55 -2.0%	$8.07	$3.52 ▼ $14.21	$70.85M	2.05	51,711 shs	2,469 shs
ZYBT Zhengye Biotechnology	$1.65 +1.2%	$1.51	$0.62 ▼ $11.45	$78.19M	-2.56	2.03 million shs	6,901 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	+15.67%	+25.68%	-6.54%	-24.81%	-63.10%
CING Cingulate	+1.36%	-4.04%	+6.53%	+16.26%	+41.08%
LONA Athira Pharma	+0.39%	-2.41%	+0.52%	-6.33%	+769,999,900.00%
ZYBT Zhengye Biotechnology	0.00%	-7.39%	+27.34%	+96.27%	-83.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	1.00	Sell	N/A	N/A
CING Cingulate	2.50	Moderate Buy	$27.00	423.76% Upside
LONA Athira Pharma	2.50	Moderate Buy	$17.33	129.73% Upside
ZYBT Zhengye Biotechnology	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ABVC, ZYBT, CING, and LONA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/23/2026	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$10.00 ➝ $9.00
8/19/2026	LONA Athira Pharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$16.00 ➝ $15.00
8/18/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	LONA Athira Pharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$18.00 ➝ $17.00
8/7/2026	LONA Athira Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/30/2026	LONA Athira Pharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$18.00
7/24/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	ZYBT Zhengye Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
7/9/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/15/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/11/2026	ZYBT Zhengye Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	49.38	N/A	N/A	$0.46 per share	2.05
CING Cingulate	N/A	N/A	N/A	N/A	$1.61 per share	N/A
LONA Athira Pharma	N/A	N/A	N/A	N/A	$3.58 per share	N/A
ZYBT Zhengye Biotechnology	$16.64M	4.70	N/A	N/A	$0.93 per share	1.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$7.91M	-$0.30	N/A	N/A	N/A	N/A	-47.68%	-30.97%	11/16/2026 (Estimated)
CING Cingulate	-$22.45M	-$3.59	N/A	N/A	N/A	N/A	-238.40%	-128.67%	11/12/2026 (Estimated)
LONA Athira Pharma	-$105.61M	-$4.21	N/A	N/A	N/A	N/A	-411.58%	-225.73%	N/A
ZYBT Zhengye Biotechnology	-$9.98M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ABVC, ZYBT, CING, and LONA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	LONA Athira Pharma	-$0.60	-$0.80	-$0.20	-$0.80	N/A	N/A
8/13/2026	Q2 2026	CING Cingulate	-$0.63	-$0.45	+$0.18	-$0.45	$0.17 million	N/A
8/12/2026	Q2 2026	ABVC ABVC BioPharma	-$0.40	-$0.03	+$0.37	-$0.03	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
CING Cingulate	N/A	N/A	N/A	N/A	N/A
LONA Athira Pharma	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.07	0.07
CING Cingulate	N/A	3.50	3.50
LONA Athira Pharma	N/A	7.01	7.01
ZYBT Zhengye Biotechnology	0.03	1.14	0.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
CING Cingulate	41.31%
LONA Athira Pharma	57.12%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	19.00%
CING Cingulate	5.30%
LONA Athira Pharma	25.73%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	26.65 million	21.59 million	Not Optionable
CING Cingulate	20	14.54 million	13.77 million	Not Optionable
LONA Athira Pharma	40	9.39 million	6.98 million	No Data
ZYBT Zhengye Biotechnology	278	47.39 million	N/A	N/A

ABVC, ZYBT, CING, and LONA Headlines

Recent News About These Companies

Zhengye Biotechnology Holding Ltd (ZYBT)

August 28, 2026 | ru.investing.com

Zhengye Biotechnology Regains Nasdaq Minimum Bid Price Compliance

August 6, 2026 | tipranks.com

Why Zhengye Biotechnology Holding (ZYBT) Stock Is Up Today

August 5, 2026 | quiverquant.comQ

Zhengye Biotechnology Stock Short Interest Report | NASDAQ:ZYBT | Benzinga

July 23, 2026 | benzinga.com

Zhengye Biotechnology Addresses Unusual Nasdaq Trading Activity

July 21, 2026 | tipranks.com

Zhengye Biotechnology says no material events behind unusual trading activity (NASDAQ: ZYBT)

July 21, 2026 | msn.com

Zhengye Biotechnology Holding Limited Says It Is Unaware of Material Non-Public Information Amid Unusual Trading Activity

July 21, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity

July 21, 2026 | globenewswire.com

Why Zhengye Biotechnology Holding Limited (ZYBT) Stock Is Up Today

July 20, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Ltd. Class A

July 13, 2026 | cnn.com

Zhengye Biotechnology Faces Nasdaq Minimum Bid Price Deficiency After May 29 Notice

June 4, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

June 4, 2026 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

April 28, 2026 | prnewswire.com

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026

April 6, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

April 6, 2026 | globenewswire.com

Zhengye Biotechnology Holding Ltd ZYBT

March 28, 2026 | morningstar.comM

Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM

March 25, 2026 | tipranks.com

Zhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGM

February 23, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders

February 11, 2026 | markets.businessinsider.com

Zhengye Biotechnology Holding Limited Highlights 2025 Achievements and 2026 Strategic Plan in Shareholder Letter

February 10, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ABVC, ZYBT, CING, and LONA Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$0.94 -0.06 (-5.50%)

As of 10:34 AM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Cingulate NASDAQ:CING

$5.16 -0.07 (-1.25%)

As of 10:35 AM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Athira Pharma NASDAQ:LONA

$7.54 -0.16 (-2.01%)

As of 10:25 AM Eastern

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Zhengye Biotechnology NASDAQ:ZYBT

$1.65 +0.02 (+1.23%)

As of 10:33 AM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABVC, ZYBT, CING, and LONA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABVC, ZYBT, CING, and LONA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABVC, ZYBT, CING, and LONA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABVC, ZYBT, CING, and LONA Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Cingulate NASDAQ:CING

Athira Pharma NASDAQ:LONA

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABVC, ZYBT, CING, and LONA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABVC, ZYBT, CING, and LONA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABVC, ZYBT, CING, and LONA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABVC, ZYBT, CING, and LONA Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Cingulate NASDAQ:CING

Athira Pharma NASDAQ:LONA

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools